Comparable stake leader
FMR LLC
SEC ownership of Atea Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001593899.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Symbol
- AVIR on Nasdaq
- SEC evidence covered
- 13D/G, 13F, and 3/4/5
- Largest SEC-reported holder
- FMR LLC
- Latest 13D/G holder
- FMR LLC
- Latest parsed evidence date
- 31 Mar 2026
- CIK
- 0001593899
- Location
- Boston, MA
Ownership snapshot
2 signals
Issuer
2 identity fields
Ownership snapshot
Top shareholders of Atea Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
FMR LLC
15%
Jean-Pierre Sommadossi
10%
BML Investment Partners, L.P.
9.9%
BlackRock, Inc.
7.1%
Bradley L. Radoff
4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
15%
|
$68,238,907
11,950,772 shares
|
+$16,302,575 | 31 Mar 2026 |
| Jean-Pierre Sommadossi |
13D/G
3/4/5
President, CEO, and Chairman, Director
|
10%
|
$26,185,536
8,876,453 shares
|
$0 | 31 Mar 2025 |
| BML Investment Partners, L.P. |
13D/G
Leonard Braden Michael
|
9.9%
|
$27,881,700
7,810,000 shares
|
+$2,119,466 | 31 Dec 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
7.1%
from 13D/G
|
$45,382,652
8,435,437 shares
|
— | 31 Mar 2026 |
| Bradley L. Radoff |
13D/G
Radoff Bradley Louis
|
4%
|
$9,971,295
3,380,100 shares
|
+$811,250 | 16 Apr 2025 |
| EcoR1 Capital, LLC |
13D/G
|
4%
|
$9,857,876
3,341,653 shares
|
$0 | 31 Dec 2024 |
| Andrea Corcoran |
3/4/5
Chief Financial Officer, Executive Vice President, Legal and Secretary
|
1%
|
$3,449,970
823,576 shares
mixed-class rows
|
— | 11 Mar 2026 |
| BML Capital Management, LLC |
13F
Company
|
8.9%
|
$37,975,575
7,058,657 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$25,446.
Buys
$25,446
Insiders: 1
Sells
$0
Insiders: 0
Net
+$25,446
Shares: +6,100
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 6,100
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 6,100 | 0 | $25,446 | $0 | +$25,446 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Atea Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Jean-Pierre Sommadossi
Net 12M change
+$25,446
Latest report
18 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jean-Pierre Sommadossi | President, CEO, and Chairman, Director | $22,198,343 | Mixed | 31 Jan 2026 | ||
| Andrea Corcoran | Chief Financial Officer, Executive Vice President, Legal and Secretary | $3,449,970 | Mixed | 11 Mar 2026 | ||
| Franklin M. Berger | Director | $1,526,418 | Mixed | 20 Jun 2025 | ||
| John Vavricka | Chief Commercial Officer | $671,526 | Mixed | 31 Jan 2026 | ||
| Janet Mj Hammond | Chief Development Officer | $575,724 | Mixed | 31 Jan 2026 | ||
| Polly A. Murphy | Director | $502,782 | +$25,446 | +5.3% | Mixed | 18 May 2026 |
| Maria Arantxa Horga | Chief Medical Officer | $437,239 | Mixed | 31 Jan 2026 | ||
| Bruno Lucidi | Director | $419,989 | Mixed | 20 Jun 2025 | ||
| Bruce Polsky | Director | $385,928 | Mixed | 20 Jun 2025 | ||
| Wayne Foster | EVP, Chief Accounting Officer | $363,245 | Mixed | 31 Jan 2026 | ||
| Barbara Gayle Duncan | Director | $279,489 | Mixed | 20 Jun 2025 | ||
| Jerome M. Adams | Director | $279,489 | Mixed | 20 Jun 2025 | ||
| Arthur S. Kirsch | Director | $139,873 | Mixed | 20 Feb 2025 | ||
| Howard Berman | Director | Mixed | 20 Jun 2025 |
Recent insider transactions for Atea Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Polly A. Murphy | AVIR | Common Stock | Purchase | 7.09% | $25,446 | $4.17 | 6,100 | 92,145 | 18 May 2026 | Direct |
| Andrea Corcoran | AVIR | Common Stock | Options Exercise | 7.86% | 60,000 | 823,576 | 11 Mar 2026 | Direct | ||
| Andrea Corcoran | AVIR | Stock Option (Right to Buy) | Options Exercise | 60,000 | 0 | 11 Mar 2026 | Direct | |||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Options Exercise | 64.1% | 300,000 | 767,830 | 03 Feb 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Stock Option (Right to Buy) | Options Exercise | -100% | -300,000 | 0 | 03 Feb 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Common Stock | Tax liability | -14.3% | -16,073 | 96,086 | 31 Jan 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Common Stock | Options Exercise | 84.2% | 51,283 | 112,159 | 31 Jan 2026 | Direct | ||
| Maria Arantxa Horga | AVIR | Stock Option (Right to Buy) | Award | 173,500 | 173,500 | 31 Jan 2026 | Direct | |||
| Maria Arantxa Horga | AVIR | Restricted Stock Units | Options Exercise | -100% | -51,283 | 0 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Common Stock | Tax liability | -12.3% | -11,570 | 82,594 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Common Stock | Options Exercise | 80.8% | 42,083 | 94,164 | 31 Jan 2026 | Direct | ||
| John Vavricka | AVIR | Stock Option (Right to Buy) | Award | 119,520 | 119,520 | 31 Jan 2026 | Direct | |||
| John Vavricka | AVIR | Restricted Stock Units | Options Exercise | -100% | -42,083 | 0 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Common Stock | Tax liability | -9.97% | -14,136 | 127,665 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Common Stock | Options Exercise | 69.3% | 58,050 | 141,801 | 31 Jan 2026 | Direct | ||
| Janet Mj Hammond | AVIR | Stock Option (Right to Buy) | Award | 177,000 | 177,000 | 31 Jan 2026 | Direct | |||
| Janet Mj Hammond | AVIR | Restricted Stock Units | Options Exercise | -100% | -58,050 | 0 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Common Stock | Tax liability | -13.3% | -12,132 | 79,329 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Common Stock | Options Exercise | 82.4% | 41,333 | 91,461 | 31 Jan 2026 | Direct | ||
| Wayne Foster | AVIR | Stock Option (Right to Buy) | Award | 108,000 | 108,000 | 31 Jan 2026 | Direct | |||
| Wayne Foster | AVIR | Restricted Stock Units | Options Exercise | -100% | -41,333 | 0 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Common Stock | Tax liability | -2.07% | -16,104 | 763,576 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Common Stock | Options Exercise | 7.57% | 54,866 | 779,680 | 31 Jan 2026 | Direct | ||
| Andrea Corcoran | AVIR | Stock Option (Right to Buy) | Award | 180,000 | 180,000 | 31 Jan 2026 | Direct | |||
| Andrea Corcoran | AVIR | Restricted Stock Units | Options Exercise | -100% | -54,866 | 0 | 31 Jan 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Tax liability | -18.5% | -106,093 | 467,830 | 31 Jan 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Common Stock | Options Exercise | 90.7% | 272,983 | 573,923 | 31 Jan 2026 | Direct | ||
| Jean-Pierre Sommadossi | AVIR | Restricted Stock Units | Options Exercise | -100% | -272,983 | 0 | 31 Jan 2026 | Direct | ||
| Polly A. Murphy | AVIR | Common Stock | Options Exercise | 52.4% | 29,600 | 86,045 | 20 Jun 2025 | Direct | ||
| Polly A. Murphy | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Polly A. Murphy | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Polly A. Murphy | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Barbara Gayle Duncan | AVIR | Common Stock | Options Exercise | 89.3% | 29,600 | 62,750 | 20 Jun 2025 | Direct | ||
| Barbara Gayle Duncan | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Barbara Gayle Duncan | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Barbara Gayle Duncan | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Franklin M. Berger | AVIR | Common Stock | Options Exercise | 6.21% | 29,600 | 506,497 | 20 Jun 2025 | Direct | ||
| Franklin M. Berger | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Franklin M. Berger | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Franklin M. Berger | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Bruce Polsky | AVIR | Common Stock | Options Exercise | 45.1% | 29,600 | 95,206 | 20 Jun 2025 | Direct | ||
| Bruce Polsky | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Bruce Polsky | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Bruce Polsky | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Jerome M. Adams | AVIR | Common Stock | Options Exercise | 89.3% | 29,600 | 62,750 | 20 Jun 2025 | Direct | ||
| Jerome M. Adams | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct | ||
| Jerome M. Adams | AVIR | Stock Option (Right to Buy) | Award | 41,200 | 41,200 | 20 Jun 2025 | Direct | |||
| Jerome M. Adams | AVIR | Restricted Stock Units | Award | 29,600 | 29,600 | 20 Jun 2025 | Direct | |||
| Bruno Lucidi | AVIR | Common Stock | Options Exercise | 35.6% | 29,600 | 112,750 | 20 Jun 2025 | Direct | ||
| Bruno Lucidi | AVIR | Restricted Stock Units | Options Exercise | -100% | -29,600 | 0 | 20 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.